Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Bausch Health Companies Inc. (BHC.TO)
Laval, QC, CA
Bausch Health Companies Inc. is a global healthcare enterprise dedicated to the creation, production, and sale of a diverse array of pharmaceutical, medical device, and over-the-counter items. Its primary therapeutic focus areas include eye health, digestive system issues, and dermatological conditions. The company's operations are strategically organized into five key divisions: Bausch + Lomb, which specializes in vision care, surgical solutions, and ophthalmic pharmaceuticals; Salix, concentrating on gastroenterology products within the United States; International Rx, offering a broad portfolio encompassing Solta products, branded and generic pharmaceuticals, OTC items, medical devices, and Bausch + Lomb offerings across numerous international markets in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East; Ortho Dermatologics, providing dermatological products in the U.S. and Solta medical aesthetic devices globally; and Diversified Products, covering pharmaceutical products in neurology and other therapeutic classes, alongside generic and dentistry items in the United States. Previously known as Valeant Pharmaceuticals International, Inc., the company adopted its current name in July 2018 and maintains its headquarters in Laval, Canada.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -6.98% | -5.05% | -5.66% | -7.91% | -24.43% | -23.08% | +9.57% | -5.42% | -78.38% | -77.05% | -26.24% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 0 | 0 |
| Hold | 8 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+8.5% ★ Q1'26: +9.9% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+458.3% ★ Q1'26: -2,262.5% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+8.9% Q1'26: +3.3% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+21.3% ★ Q1'26: +20.6% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+6.6% ★ Q1'26: +11.1% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+1.9% Q1'26: +2.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×6.14× Q1'26: 6.48× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 5 Rev. Ana. 6 EPS Ana. |
Dec 2027 6 Rev. Ana. 7 EPS Ana. |
Dec 2028 2 Rev. Ana. 5 EPS Ana. |
Dec 2029 5 Rev. Ana. 2 EPS Ana. |
Dec 2030 3 Rev. Ana. 5 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
10.50B
est: 14.51B (-27.7%)
|
9.67B
est: 12.65B (-23.6%)
|
8.72B
est: 11.01B (-20.8%)
|
8.38B
est: 11.03B (-24.1%)
|
8.60B
est: 11.30B (-23.9%)
|
8.03B
est: 10.19B (-21.2%)
|
8.43B
est: 10.61B (-20.5%)
|
8.12B
est: 10.91B (-25.5%)
|
8.76B
est: 11.67B (-25.0%)
|
9.63B
est: 9.59B (+0.4%)
|
10.45B
est: 10.25B (+1.9%)
|
10.48B
10.44B – 10.56B
+2.3% YoY
|
10.48B
10.36B – 10.67B
0.0% YoY
|
9.59B
9.52B – 9.72B
-8.4% YoY
|
9.50B
9.43B – 9.62B
-1.0% YoY
|
9.47B
9.39B – 9.59B
-0.3% YoY
|
| EBITDA |
5.11B
est: 4.61B (+10.8%)
|
2.27B
est: 4.02B (-43.6%)
|
3.41B
est: 3.50B (-2.4%)
|
350.00M
est: 3.50B (-90.0%)
|
1.85B
est: 3.59B (-48.4%)
|
2.43B
est: 3.24B (-25.1%)
|
3.26B
est: 3.37B (-3.3%)
|
2.88B
est: 3.46B (-16.9%)
|
2.20B
est: 3.71B (-40.6%)
|
2.82B
est: 3.10B (-8.9%)
|
3.45B
est: 3.31B (+4.2%)
|
3.39B
3.37B – 3.41B
+2.3% YoY
|
3.39B
3.35B – 3.45B
0.0% YoY
|
3.10B
3.08B – 3.14B
-8.4% YoY
|
3.07B
3.05B – 3.11B
-1.0% YoY
|
3.06B
3.04B – 3.10B
-0.3% YoY
|
| EBIT |
1.41B
est: 2.11B (-33.4%)
|
-599.00M
est: 1.84B (-132.5%)
|
99.00M
est: 1.60B (-93.8%)
|
-2.47B
est: 1.61B (-253.6%)
|
-225.00M
est: 1.65B (-113.7%)
|
600.00M
est: 1.49B (-59.6%)
|
402.00M
est: 1.55B (-74.0%)
|
1.34B
est: 1.59B (-16.0%)
|
938.00M
est: 1.70B (-44.8%)
|
1.56B
est: 1.66B (-6.4%)
|
2.22B
est: 1.78B (+25.1%)
|
1.82B
1.81B – 1.83B
+2.3% YoY
|
1.82B
1.80B – 1.85B
0.0% YoY
|
1.66B
1.65B – 1.68B
-8.4% YoY
|
1.65B
1.63B – 1.67B
-1.0% YoY
|
1.64B
1.63B – 1.66B
-0.3% YoY
|
| Net Income |
-266.20M
est: 3.75B (-107.1%)
|
-2.41B
est: 1.94B (-223.9%)
|
2.40B
est: 1.40B (+71.3%)
|
-4.15B
est: 1.46B (-384.9%)
|
-1.78B
est: 1.59B (-212.1%)
|
-559.00M
est: 1.38B (-140.6%)
|
-937.00M
est: 1.54B (-161.0%)
|
-212.00M
est: 1.10B (-119.2%)
|
-592.00M
est: 1.27B (-146.6%)
|
-46.00M
est: 1.40B (-103.3%)
|
159.75M
est: 1.45B (-89.0%)
|
1.59B
1.48B – 1.74B
+9.1% YoY
|
1.53B
1.28B – 1.88B
-3.7% YoY
|
1.01B
995.63M – 1.02B
-34.2% YoY
|
1.05B
1.04B – 1.07B
+4.9% YoY
|
1.14B
1.13B – 1.16B
+8.3% YoY
|
| SGA |
2.68B
est: 4.66B (-42.4%)
|
2.81B
est: 4.06B (-30.8%)
|
2.58B
est: 3.53B (-27.0%)
|
2.47B
est: 3.54B (-30.2%)
|
2.55B
est: 3.63B (-29.5%)
|
2.37B
est: 3.27B (-27.6%)
|
2.62B
est: 3.41B (-23.0%)
|
2.63B
est: 3.50B (-25.0%)
|
2.92B
est: 3.75B (-22.1%)
|
3.30B
est: 3.15B (+4.5%)
|
3.50B
est: 3.37B (+3.7%)
|
3.45B
3.43B – 3.47B
+2.3% YoY
|
3.45B
3.41B – 3.51B
0.0% YoY
|
3.16B
3.13B – 3.20B
-8.4% YoY
|
3.12B
3.10B – 3.16B
-1.0% YoY
|
3.11B
3.09B – 3.15B
-0.3% YoY
|
| EPS |
-0.78
est: 10.19 (-107.7%)
|
-6.94
est: 5.28 (-231.3%)
|
8.63
est: 3.81 (+126.4%)
|
-11.86
est: 3.96 (-399.8%)
|
-5.07
est: 4.32 (-217.3%)
|
-1.58
est: 3.74 (-142.3%)
|
-2.61
est: 4.17 (-162.5%)
|
-0.59
est: 3.00 (-119.7%)
|
-1.62
est: 3.45 (-146.9%)
|
-0.12
est: 3.75 (-103.2%)
|
0.43
est: 3.87 (-88.9%)
|
4.23
3.94 – 4.65
+9.1% YoY
|
4.07
3.42 – 5.01
-3.7% YoY
|
2.68
2.66 – 2.73
-34.2% YoY
|
2.81
2.79 – 2.86
+4.9% YoY
|
3.05
3.02 – 3.10
+8.3% YoY
|
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-04-27 | RBC Capital | Sector Perform | Sector Perform | Maintain |
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Fidelity Canadian High Quality ETF FCCQ.TO | 1.46% | 10.24M | 0.39% |
| 2 | Fidelity Canadian Value ETF FCCV.TO | 1.35% | 11.36M | 0.39% |
| 3 | Inspire Fidelis Multi Factor ETF FDLS | 0.98% | 2.26M | 0.66% |
| 4 | Fidelity All-Canadian Equity ETF FCCA.NE | 0.83% | 1.20M | 0.39% |
| 5 | iShares S&P/TSX SmallCap Index ETF XCS.TO | 0.59% | 1.01M | 0.60% |
| 6 | Desjardins RI Canada Multifactor - Net-Zero Emissions Pathway ETF DRFC.TO | 0.39% | 1.01M | 0.40% |
| 7 | iShares S&P/TSX Completion Index ETF XMD.TO | 0.18% | 1.00M | 0.60% |
| 8 | Fidelity All-in-One Growth ETF FGRO.NE | 0.17% | 5.85M | 0.42% |
| 9 | Fidelity All-in-One Balanced ETF FBAL.NE | 0.12% | 7.92M | 0.41% |
| 10 | Fidelity All-in-One Conservative ETF FCNS.NE | 0.08% | 1.24M | 0.40% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Thomas J. Appio | Chief Executive Officer & Director | 5M | male |
| Jean-Jacques Charhon | Executive Vice President & Chief Financial Officer | 2M | male |
| Seana Carson | Executive Vice President & General Counsel | 2M | female |
| Aimee J. Lenar | Executive Vice President of US Pharma | 2M | female |
| Jonathan Sadeh | Executive Vice President, Chief Medical Officer and Head of R&D | — | — |
| Kathleen Fitzpatrick | Executive Vice President and Chief HR & Communications Officer | — | female |
| Mirza Dautbegovic | Executive Vice President & Chief Operating Officer | — | male |
| Steven Lee | Senior Vice President, Controller & Chief Accounting Officer | — | male |
| William N. Woodfield | Senior Vice President & Treasurer | — | male |
| Cees Heiman | Senior Vice President of Europe & Canada | — | male |
| Garen Sarafian | Vice President & Head of Investor Relations | — | male |
| Jiny Kim | Senior Vice President of Solta Medical | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for BHC.TO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
